Induction of Allergen Specific Bronchial Immunotolerance After Specific

Status Completed

Clinical Trial Summary

One aim of this study was to find out if the bronchial allergen provocation (BAP) is an appropriate method to appraise the efficacy of a specific immunotherapy (SIT). The investigators had one group of children receiving SIT and one group of patients who denied a SIT although they had an indication for it. Retrospectively the investigators analysed the data of the first BAP and blood parameters specific IgE-mite, total IgE before SIT (November 2008 till February 2010). Prospectively The investigators analysed the lung parameters and allergic labor parameters that we got in the course of the second BAP. The investigators mean parameter was PD20FEV1-mite. Another aim of The investigators study was to find specific immunological differences between children who improved because of SIT and those who showed no improvement. Thus, The investigators compared the levels of total IgE, cumulative IgE-mite and specific IgE-mite before and after SIT and the levels of specific IgG-mite and specific IgG4-mite after SIT.

Clinical Trial Description

One aim of this study was to find out if the bronchial allergen provocation(BAP) is an appropriate method to appraise the efficacy of a specific immunotherapy (SIT). We had one group of children receiving SIT and one group of patients who denied a SIT although they had an indication for it. Retrospectively we analysed the data of the first BAP (PD20FEV1, VC, FEV1, FEV1/VC (%), eNO) and allergic blood parameters like specific IgE-mite, total IgE, cumulative IgE before SIT (November 2008 till February 2010). Prospectively we analysed the lung parameters and allergic labor parameters that we got in the course of the second BAP. Our mean parameter was PD20FEV1-mite. Another aim of our study was to find specific immunological differences between children who improved because of SIT and those who showed no improvement. Thus, we compared the levels of total IgE, cumulative IgE-mite and specific IgE-mite before and after SIT and the levels of specific IgG-mite and specific IgG4-mite after SIT. Additionally all patients answered a questionnaire according to ISAAC about their clinical symptoms, their quality of life and their medication score. ;

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01479205
Study type	Observational
Source	Johann Wolfgang Goethe University Hospitals
Contact
Status	Completed
Phase	N/A
Start date	July 2010
Completion date	September 2011

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03850626` - Validation of Combined Symptom Medication Score (cSMS) in Allergic Patients
Completed	`NCT02911688` - Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled O3 Exposure	Phase 2
Active, not recruiting	`NCT01776177` - The REALITY Study - a Real-life Long-term Analysis of Xolair Therapy	N/A
Completed	`NCT00485576` - Safety and Efficacy Study of Eculizumab in Patients With Mild Allergic Asthma	Phase 2
Completed	`NCT00736801` - Effect of Salmeterol on Brain-Derived Neurotrophic Factor (BDNF) Concentrations in Asthma	N/A
Completed	`NCT00515775` - Influence of a Inhaled Corticosteroid Therapy Versus Corticosteroid + LABA Therapy on the FeNO of Asthmatic Children	N/A
Completed	`NCT04259164` - Anti-inflammatory Effects Glycopyrronium	Phase 3
Active, not recruiting	`NCT04619017` - Airway Immune Response to Allergens (Use Lay Language Here)	Phase 1
Completed	`NCT01699594` - Change in Airway Responsiveness After Allergen Exposure	N/A
Completed	`NCT00999466` - The Tolerability and Effects of AZD8848 in Allergic Asthma Subjects Challenged With Inhaled Allergen	Phase 2
Completed	`NCT01353755` - 2nd Pivotal Study rPhleum - Adults and Adolescents With Rhinoconjunctivitis +/-Controlled Asthma	Phase 3
Completed	`NCT00434434` - A Study of Omalizumab in the Prevention of Allergen Induced Airway Obstruction in Adults With Mild Allergic Asthma	Phase 2
Completed	`NCT00492076` - Efficacy and Safety Trial of Subcutaneous Immunotherapy in Mite Induced Asthma	Phase 4
Completed	`NCT00490425` - Prevention of Asthma and Allergy by Probiotic Lactobacillus GG	Phase 4
Completed	`NCT00829179` - Role of RhuMab-E25 in Reducing Exhaled Nitric Oxide (NO) in Allergic Asthma	Phase 3
Recruiting	`NCT04542902` - Non-coding RNAs Analysis of Eosinophil Subtypes in Asthma	N/A
Recruiting	`NCT04109534` - Effect of a Dietary Fatty Acid Supplementation on Symptoms and Bronchial Inflammation in Patients With Asthma	N/A
Active, not recruiting	`NCT05186025` - Tyrosine Allergoid Paediatric and Adult Study
Withdrawn	`NCT03307278` - House Dust Mite Induced Inflammasome Activation on Corticosteroid Resistance	N/A
Enrolling by invitation	`NCT06151938` - Evaluate Measurement Instruments Relevance in Assessing Effectiveness of ACARIZAX® in House Dust Mite Allergic Rhinitis

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Induction of Allergen Specific Bronchial Immunotolerance After Specific Immunotherapy — ITASIT

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms